Matching articles for "Atacand"
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • June 12, 2023; (Issue 1678)
...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Atogepant (Qulipta) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • November 1, 2021; (Issue 1636)
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults....
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • June 14, 2021; (Issue 1626)
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)
...
View the Comparison Table: Some Drugs for HFrEF
Eptinezumab (Vyepti) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • June 1, 2020; (Issue 1599)
The FDA has approved eptinezumab-jjmr (Vyepti –
Lundbeck), a calcitonin gene-related peptide (CGRP)
antagonist administered IV once every 3 months, for
migraine prevention in adults. It is the fourth...
The FDA has approved eptinezumab-jjmr (Vyepti –
Lundbeck), a calcitonin gene-related peptide (CGRP)
antagonist administered IV once every 3 months, for
migraine prevention in adults. It is the fourth monoclonal
antibody to be approved for this indication; erenumab
(Aimovig), fremanezumab (Ajovy), and galcanezumab
(Emgality), which are all given subcutaneously once
monthly (fremanezumab can also be given once every 3
months), were approved earlier.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 18, 2020; (Issue 1598)
Drugs available for treatment of chronic hypertension
and their dosages, adverse effects, and costs are
listed in the tables. Treatment
of hypertensive urgencies and emergencies is not
discussed...
Drugs available for treatment of chronic hypertension
and their dosages, adverse effects, and costs are
listed in the tables. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are...
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are considered to have
heart failure with preserved ejection fraction (HFpEF).
There is little evidence that drug treatment improves
clinical outcomes in patients with HFpEF.
Expanded Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)
...
View the Expanded Table: Some Drugs for HFrEF
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • March 13, 2017; (Issue 1516)
in the US and their dosages, adverse effects, and
costs are listed in the tables.
Treatment of hypertensive urgencies and emergencies
is not discussed...
in the US and their dosages, adverse effects, and
costs are listed in the tables.
Treatment of hypertensive urgencies and emergencies
is not discussed here.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use...
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use of
a triptan early in an attack when pain is still mild to
moderate in intensity improves headache response
and reduces recurrence rates.
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Byvalson - A Beta Blocker/ARB Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • September 12, 2016; (Issue 1503)
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment...
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment of
hypertension. It is the only combination product that
contains nebivolol, and the first to combine a beta
blocker with an ARB.
Sacubitril/Valsartan (Entresto) for Heart Failure
The Medical Letter on Drugs and Therapeutics • August 3, 2015; (Issue 1474)
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular...
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular death
and heart failure hospitalization in patients with
heart failure with reduced ejection fraction. Sacubitril
is the first neprilysin inhibitor to become available in
the US.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 19, 2015; (Issue 1460)
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure...
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF) or systolic heart failure. Patients
with a LVEF ≥50% and symptoms of heart failure
are considered to have heart failure with preserved
ejection fraction (HFpEF) or diastolic heart failure;
there is little evidence that drug treatment improves
clinical outcomes in these patients. The treatment of
acute heart failure is not included here.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • September 1, 2012; (Issue 121)
Chronic systolic heart failure is usually associated with
a left ventricular ejection fraction (LVEF) of ≤40%.
Many patients with symptoms of heart failure have
higher ejection fractions, but there is no...
Chronic systolic heart failure is usually associated with
a left ventricular ejection fraction (LVEF) of ≤40%.
Many patients with symptoms of heart failure have
higher ejection fractions, but there is no evidence that
drug treatment of heart failure with preserved systolic
function (LVEF >40%) improves clinical outcomes.
Some of the drugs commonly used now for treatment of
chronic heart failure are listed in the table on page 71.
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • March 5, 2012; (Issue 1385)
The FDA has approved a fixed-dose combination of
the angiotensin receptor blocker (ARB) azilsartan and
the thiazide-like diuretic chlorthalidone as Edarbyclor
(Takeda) for treatment of...
The FDA has approved a fixed-dose combination of
the angiotensin receptor blocker (ARB) azilsartan and
the thiazide-like diuretic chlorthalidone as Edarbyclor
(Takeda) for treatment of hypertension
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • January 1, 2012; (Issue 113)
Drugs available in the US for treatment of chronic
hypertension, with their dosages and adverse effects,
are listed in the tables that begin on page 2.
Combination products are listed on page 8. Drugs...
Drugs available in the US for treatment of chronic
hypertension, with their dosages and adverse effects,
are listed in the tables that begin on page 2.
Combination products are listed on page 8. Drugs for
treatment of hypertensive emergencies are not discussed
here. They were reviewed previously.
Azilsartan Medoxomil (Edarbi) - The Eighth ARB
The Medical Letter on Drugs and Therapeutics • May 16, 2011; (Issue 1364)
The angiotensin receptor blocker (ARB) azilsartan
medoxomil (Edarbi – Takeda) was recently approved
by the FDA for oral treatment of hypertension, either
alone or combined with other drugs. It is the...
The angiotensin receptor blocker (ARB) azilsartan
medoxomil (Edarbi – Takeda) was recently approved
by the FDA for oral treatment of hypertension, either
alone or combined with other drugs. It is the eighth
ARB approved for this indication.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • February 1, 2011; (Issue 102)
Drugs for treatment of migraine are listed in Table 2
on page 9. Drugs for prevention of migraine are listed
in Table 3 on page 10. Treatment of migraine in the
emergency room, which may involve use of...
Drugs for treatment of migraine are listed in Table 2
on page 9. Drugs for prevention of migraine are listed
in Table 3 on page 10. Treatment of migraine in the
emergency room, which may involve use of intravenous
drugs, is not included here.
Drugs for Treatment of Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • July 1, 2009; (Issue 83)
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as...
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • January 1, 2009; (Issue 77)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • March 1, 2008; (Issue 67)
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve...
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Drugs for Treatment of Heart Failure
The Medical Letter on Drugs and Therapeutics • January 1, 2006; (Issue 41)
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the...
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • June 1, 2005; (Issue 34)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
ARBs and Myocardial Infarction
The Medical Letter on Drugs and Therapeutics • May 9, 2005; (Issue 1208)
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough....
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • September 1, 2004; (Issue 25)
Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004;...
Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004; 63:520). Drugs for prevention of migraine are listed in the table on page 65. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Initial Therapy of Hypertension
The Medical Letter on Drugs and Therapeutics • July 5, 2004; (Issue 1186)
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial...
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Drugs for Treatment of Heart Failure
The Medical Letter on Drugs and Therapeutics • April 1, 2003; (Issue 8)
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as...
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • February 1, 2003; (Issue 6)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • March 5, 2001; (Issue 1099)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension
The Medical Letter on Drugs and Therapeutics • November 5, 1999; (Issue 1065)
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available...
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • March 12, 1999; (Issue 1048)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 29, 1999; (Issue 1045)
...
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Candesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • November 20, 1998; (Issue 1040)
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.